Searchable abstracts of presentations at key conferences in endocrinology

ea0026p254 | Pituitary | ECE2011

Lack of efficacy of 24-month treatment with the GH receptor antagonist pegvisomant in patient with active acromegaly resistant to long-term, high-dose somatostatin analog treatment: effects on IGF1 and GH levels

Vetri M , Tita P

In acromegaly symptom control can be achieved by lowering insulin-like growth factor 1 (IGF1) concentrations to the age-adjusted normal range. However, even with optimal surgery and current medical therapies (dopamine agonists, somatostatin analogues), 30–50% of patients do not achieve target concentrations of IGF1 and GH. Pegvisomant (PEGV), a new GH-receptor antagonist, given as s.c. injections at variable dosages, could normalises IGF1 concentrations in ~70% of acromeg...

ea0026p277 | Pituitary | ECE2011

Minimal active acromegaly may be effectively treated by prolonged injections of octreotide LAR

Zdunowski P , Zgliczynski W

In acromegaly, an excessive GH secretion by pituitary adenoma, minimal active disease may be defined as slow progression of characteristic signs and symptoms at presence of slightly elevated or normal IGF1 levels and lack of GH suppression after glucose load. Nadir post-glucose GH level defining active disease is under permanent discussion and depends on assessment methods. IGF1 reference range is wide, must be age-adjusted and often is sex-dependent. From mid-00’s excess...

ea0024s23 | Symposium 3 – The Beta cell | BSPED2010

Neonatal diabetes

Shield J P H

Neonatal diabetes or monogenic diabetes of infancy can manifest as a transient or permanent condition. TNDM is most commonly caused by imprinting disorders on chromosome 6q24 (TNDM1.Uniparental Isodisomy Chromosome 6, Paternal Duplication of 6q24, loss of maternal methylation). Recently it has been identified that over half of those with maternal hypomethylation at 6q24 have relaxed maternal methylation at other imprinted loci and that the majority of these patients have mutat...

ea0024p18 | (1) | BSPED2010

The effect of pubertal timing on later adult obesity

Prentice P , Viner R

Introduction: Obesity has become an international epidemic, with complex multifactorial aetiology. Both modifiable and unchangeable risk factors must be identified, to target public health interventions. Some studies have suggested that earlier pubertal maturation increases risk of adult obesity, although others have found no relationship. We aimed to meta-analyse existing data and hypothesised that any association is likely to be confounded by childhood adiposity.<p class...

ea0022s16.1 | Hot topics in pituitary disease | ECE2010

Pros and cons of large scale screening of Cushing's syndrome

Tabarin A , Perez P

Data from the literature suggest that endogenous Cushing’s syndrome (CS) is an unusual disorder in the general population with a reported incidence of 2–3 cases per 1 million inhabitants per year. Patients who are not cured from CS have a poor prognosis with an increased mortality due to cardiovascular disease and significant morbidity that impairs quality of life. Recently published screening studies performed in obese patients with type 2 diabetes or patients with ...

ea0021pl8biog | Clinical Endocrinology Trust Lecture | SFEBES2009

Clinical Endocrinology Trust Lecture

Clayton P E

P E Clayton, Endocrinology and Diabetes Group, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK AbstractPeter Clayton is Professor of Child Health and Paediatric Endocrinology in the Faculty of Medical and Human Sciences at the University of Manchester. He is an honorary consultant at the Royal Manchester Children’s Hospital and at the Christie Hospital and is the Director of t...

ea0019s33 | Polycystic ovarian syndrome (PCOS): when does it start, why and what to do about it? | SFEBES2009

Metformin-a storm with few good data

Koeger Kathy , Legro P

Polycystic ovary syndrome (PCOS) is a common and incompletely understood endocrinopathy in women that has both metabolic and reproductive features. Pathophysiologic constructs often guide the design and interpretation of studies by researchers and the choice of treatment by clinicians. Voids in evidence lead to consensus conferences to guide the diagnosis and treatment of the syndrome, yet these remain the lowest level of evidence. This lecture will explore the role of metform...

ea0019s34 | Phosphoinositide 3-kinase (PI3K) signalling in health and disease: an old system with new potential | SFEBES2009

Signalling from cell surface receptors: molecular mechanisms and physiological significance of the phosphoinositide 3-kinase signalling system

Hawkins P , Stephens L

Phosphoinositide 3-kinase (PI3K) signalling pathways are now accepted to be widely important in the mechanisms by which a variety of cell surface receptors can regulate critical cellular functions, such as cell growth, survival and movement. Class I PI3Ks generate the messenger lipids PtdIns(3,4,5)P3 and PtdIns(3,4)P2 in the inner leaflet of the plasma membrane. These two lipids then co-ordinate the regulation of multiple protein targets by binding, with ...

ea0019p144 | Diabetes, Metabolism and Cardiovascular | SFEBES2009

Screening for testosterone deficiency in a hospital diabetic clinic

Downie P , Ulahannan T

Background: Numerous studies have provided evidence of the link between low testosterone levels and obesity, cardiovascular disease and type 2 diabetes. A recent UK study revealed 20% of type 2 diabetics had testosterone levels <8 nmol/l and 31% between 8 and 12 nmol/l. Hypogonadism in men can present with a variety of clinical symptoms which could include erectile dysfunction (ED). However, diabetic patients infrequently volunteer information regarding ED and is often not...